¸²ÇÁÁ¾¿¬±¸È¸ CISL34 ÀÓ»ó½ÃÇè ¿¬±¸ÀÚ ¸ðÀÓ : 2023-08-26
±³À°ÀÏÀÚ : 2023-08-26
±³À°Àå¼Ò : ¼¿ï ·Ôµ¥¿ùµåŸ¿ö SKY31 ÄÁº¥¼Ç
±³À°ÁÖÁ¦ : CISL34 ÀÓ»ó½ÃÇè ¿¬±¸ÀÚ ¸ðÀÓ
ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¸²ÇÁÁ¾¿¬±¸È¸
´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581
À̸ÞÀÏ : hematology@kams.or.kr
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú
Âü¼®¿¹»óÀÎ : 60¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 3 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í Àü¹®ÀÇ 50000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 08¿ù 26ÀÏ AȦ 13:00~13:10 Brentuximab vedotin plus cisplatin, cytarabine, and dexamethasone in patients with relapsed or refractory Hodgkin¡¯s lymphoma who are eligible for transplan ÀÌÁØÈ£(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 08¿ù 26ÀÏ AȦ 13:10~13:20 Phase II study of Glofitamab, Poseltinib and Lenalidomide in patients with relapsed/refractory diffuse large B cell lymphoma º¯ÀÚ¹Î(¼¿ïÀÇ´ë )
±³À°½Ã°£ 08¿ù 26ÀÏ AȦ 13:20~13:30 CISL2204: A randomized phase II trial comparing rituximab/bendamustine (RB) alternating with rituximab/bendamustine/cytarabine (RBAC) with RB as induction therapy in elderly patients with newly diagnosed and transplant-ineligible mantle cell lymphoma ÀÓÈ£¿µ(ÀüºÏÀÇ´ë )
±³À°½Ã°£ 08¿ù 26ÀÏ AȦ 13:30~13:40 CISL2208: Duodenal-type follicular lymphoma in Korean population: A multicenter study Á¤Á¾Çå(±¹¸³¾Ï¼¾ÅÍ )
±³À°½Ã°£ 08¿ù 26ÀÏ AȦ 13:40~13:50 Phase II study of lenalidomide-R-CHOP for patients with diffuse large B cell lymphoma Á¶Çü¿ì(¿ï»êÀÇ´ë )
±³À°½Ã°£ 08¿ù 26ÀÏ AȦ 13:50~14:00 Phase II trial of Lenalidomide maintenance after high-dose methotrexate-based immunochemotherapy in patients with primary central nervous system lymphoma ÀÌÁ¤¿Á(¼¿ïÀÇ´ë )
±³À°½Ã°£ 08¿ù 26ÀÏ AȦ 14:00~14:10 Chemotherapy-free salvage therapy with rituximab, lenalidomide, and poseltinib for the treatment of relapsed or refractory primary central nervous system lymphoma À±»óÀº(¼º±Õ°üÀÇ´ë )
±³À°½Ã°£ 08¿ù 26ÀÏ AȦ 14:10~14:20 Allogeneic Stem Cell Transplantation with 3-days Busulfan plus Fludarabine as Conditioning in Patients with Relapsed or Refractory T-, NK/T-cell lymphomas ÀÌÁöÇö(µ¿¾ÆÀÇ´ë)
±³À°½Ã°£ 08¿ù 26ÀÏ AȦ 14:20~14:30 Decitabine with Gemcitabine, Oxaliplatin for relapsed/refractory peripheral T cell lymphoma º¯ÀÚ¹Î(¼¿ïÀÇ´ë )
±³À°½Ã°£ 08¿ù 26ÀÏ AȦ 14:30~14:40 Phase II study of Concurrent Tislelizumab and Radiotherapy for treatment-naive, newly diagnosed low-risk extranodal NK/T-cell lymphoma, nasal type À±»óÀº(¼º±Õ°üÀÇ´ë )
±³À°½Ã°£ 08¿ù 26ÀÏ AȦ 14:40~14:50 Phase II study of Lenalidomide Maintenance after Salvage therapy in patients with relapsed and/or refractory non-Hodgkin T-cell lymphoma ±è¼®Áø(¼º±Õ°üÀÇ´ë )
±³À°½Ã°£ 08¿ù 26ÀÏ AȦ 14:50~15:00 Phase II study of Isatuximab and Cemiplimab in relapsed or refractory natural killer/ T-cell lymphoid malignancy ±è¼®Áø(¼º±Õ°üÀÇ´ë )
±³À°½Ã°£ 08¿ù 26ÀÏ AȦ 15:00~15:10 Multicenter, open label, phase I/II study of azacitidine-CHOP for patients with nodal T-cell lymphoma with T-follicular helper phenotype ±è¼®Áø(¼º±Õ°üÀÇ´ë )
±³À°½Ã°£ 08¿ù 26ÀÏ AȦ 15:30~15:45 Real-world outcomes ofpatients with PMBCL in Korea: PET-CT incorporated retrospective analysis ÀÌÁØÈ£(Áß¾ÓÀÇ´ë )
±³À°½Ã°£ 08¿ù 26ÀÏ AȦ 15:45~16:00 International Registry of chronic active EBV infection ±è¼®Áø(¼º±Õ°üÀÇ´ë )
±³À°½Ã°£ 08¿ù 26ÀÏ AȦ 16:00~16:20 Phase 1/2 study of Selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with secondary central nervous system involving relapsed or refractory B-cell non-Hodgkin¡¯s lymphoma: a single arm, open label, multicenter study ¼Û°¡¿µ(Àü³²ÀÇ´ë )